Biogen Inc. $BIIB Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Biogen Inc. (NASDAQ:BIIB) by 5.5% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,075,757 shares of the biotechnology company’s stock after purchasing an additional 56,538 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.73% of Biogen worth $135,104,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Biogen during the 1st quarter valued at $27,000. Vision Financial Markets LLC purchased a new stake in Biogen during the first quarter valued at about $27,000. Zions Bancorporation National Association UT acquired a new stake in Biogen during the first quarter worth about $29,000. Rothschild Investment LLC raised its holdings in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares during the period. Finally, Concord Wealth Partners lifted its stake in shares of Biogen by 100.0% in the 2nd quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

BIIB stock opened at $181.94 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. Biogen Inc. has a 52-week low of $110.04 and a 52-week high of $185.17. The stock’s 50 day moving average is $153.78 and its two-hundred day moving average is $139.68. The company has a market capitalization of $26.69 billion, a PE ratio of 17.39, a P/E/G ratio of 1.17 and a beta of 0.10.

Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating the consensus estimate of $3.89 by $0.92. The company had revenue of $2.53 billion during the quarter, compared to analysts’ expectations of $2.34 billion. Biogen had a return on equity of 13.85% and a net margin of 15.31%.The business’s revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the business posted $4.08 EPS. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS. Analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 517 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the transaction, the insider directly owned 5,772 shares of the company’s stock, valued at $770,850.60. This trade represents a 8.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Guggenheim increased their target price on shares of Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Stifel Nicolaus raised shares of Biogen from a “hold” rating to a “buy” rating and increased their price objective for the stock from $144.00 to $202.00 in a research report on Thursday, November 6th. Mizuho lifted their target price on shares of Biogen from $169.00 to $177.00 and gave the company an “outperform” rating in a report on Monday, November 3rd. HC Wainwright upped their price target on shares of Biogen from $187.00 to $194.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Finally, Wells Fargo & Company boosted their price objective on Biogen from $140.00 to $155.00 in a research note on Friday, October 31st. Ten investment analysts have rated the stock with a Buy rating and seventeen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $178.96.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.